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Abstract
Background: To evaluate the effectiveness and safety of the World Health Organization antibiotic regimen for the
treatment of paucibacillary (PB) and multibacillary (MB) leprosy compared to other available regimens.
Methods: We performed a search from 1982 to July 2018 without language restriction. We included randomized
controlled trials, quasi-randomized trials, and comparative observational studies (cohorts and case-control studies)
that enrolled patients of any age with PB or MB leprosy that were treated with any of the leprosy antibiotic
regimens established by the WHO in 1982 and used any other antimicrobial regimen as a controller. Primary
efficacy outcomes included: complete clinical cure, clinical improvement of the lesions, relapse rate, treatment
failure. Data were pooled using a random effects model to estimate the treatment effects reported as relative risk
(RR) with 95% confidence intervals (CI).
Results: We found 25 eligible studies, 11 evaluated patients with paucibacillary leprosy, while 13 evaluated patients
with MB leprosy and 1 evaluated patients of both groups. Diverse regimen treatments and outcomes were studied.
Complete cure at 6 months of multidrug therapy (MDT) in comparison to rifampin-ofloxacin-minocycline (ROM)
found RR of 1.06 (95% CI 0.88–1.27) in five studies. Whereas six studies compare the same outcome at different
follow up periods between 6months and 5 years, according to the analysis ROM was not better than MDT (RR of
1.01 (95% CI 0.78–1.31)) in PB leprosy.
Conclusion: Not better treatment than the implemented by the WHO was found. Diverse outcome and treatment
regimens were studied, more statements to standardized the measurements of outcomes are needed.
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Background
Leprosy is a neglected disease caused by Mycobacterium
leprae that affects the skin and peripheral nerves.
Although treatment exists, access is limited and if it is
not initiated early in the course of the disease, the
control is suboptimal and permanent disabling sequelae
can occur [1]. On the other hand, research on leprosy is
scarce, limiting the development of new strategies. Add-
itionally, in the general population leprosy is feared and
misunderstood. Patients, who suffer this disease, since
biblical times, are victims of ostracism, stigma and neg-
lect in many cases [2].
Even when the prevalence of this disease has significantly
decreased, and most previously highly endemic countries
have reached erradication (defined as a registered preva-
lence rate of < 1 case/10000 population), it continues to be
a global health concern [3]. In 2014, the World Health
Organization (WHO) estimated that 213,899 new patients
were diagnosed globally. Most of them come from develop-
ing countries such as Brazil, India and Indonesia. These
nations accounted for 81% of new cases [4].
The best treatment regimen available continues to be
controversial with limited evidence support. In 1981, the
WHO developed, by consensus, a multidrug therapy
(MDT) with dapsone and rifampin for 6 to 12months
for paucibacillary (PB) while clofazimine was added and
the length of therapy extended to 24months for multi-
bacillary (MB) leprosy [5]. These recommendations were
reformulated in 1998, reducing the treatment duration
to 6 and 12 months respectively, mainly based on eco-
nomic reasons [6]. On the other hand, the National
Hansen’s Diseases Programs (NHDP) in Peru continues
to favors a longer duration of therapy [7]. Recently,
other drugs as minocycline, ofloxacin, levofloxacin, clari-
thromycin and moxifloxacin have shown to be effective
against M. leprae [8].
Considering the lack of an accurate quantitative end-
point (noncultivable pathogen), and a very long observa-
tion period for identification of relapse (approximately
15 to 20 years), conducting a trial to compare antibiotic
regimens in this disease results extremely difficult, lead-
ing to a weakness and lack of evidence. Therefore, we
conducted a systematic review to evaluate the effective-
ness and safety of the WHO antibiotic regimen for the
treatment of PB and MB leprosy compared to other
available regimens.
Methods
This review was reported following the Systematic Re-
views and Meta-Analyses (PRISMA) guidelines [9].
Eligibility criteria
Following our predesign protocol we included random-
ized controlled trials (RCTs), quasi-randomized trials,
and comparative observational studies (cohorts and
case-control studies) that enrolled patients of any age
with PB or MB leprosy who were treated with any of the
leprosy antibiotic regimens established by the WHO in
1982 and used any other antimicrobial regimen as a
controller.
Information sources and search
An experienced librarian (LJP) with expertise in con-
ducting systematic reviews designed and conducted the
electronic search strategy with input from the study in-
vestigators. We searched multiple electronic databases
(Ovid Medline In-Process & Other Non-Indexed Cita-
tions, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane
Database of Systematic Reviews, Ovid Cochrane Central
Register of Controlled Trials, Scopus, and LILACS) from
1982 to July 2018 without any language restriction. Con-
trolled vocabulary supplemented with keywords was
used to search for the topics of leprosy and WHO multi-
drug therapy (MDT), as well as to limit the search to
randomized trials and observational studies conducted
in humans. The detailed search strategy is listed in
Additional file 1. This search was complemented by a
manual search that included, reviewing the reference
lists of the eligible primary studies, narrative reviews and
queried experts.
Study selection
Two independent reviewers screened all abstracts and
titles and selected potentially eligible studies for full-text
assessment. Disagreements were included during this
phase. Upon retrieval of the full text version of poten-
tially eligible studies, the review process was repeated
using pre-defined eligibility criteria. Disagreements were
resolved by consensus (reviewers discussed the study
and reached a consensus); when this was not possible,
by arbitration (a third reviewer). We achieved almost
perfect agreement (k = 0.9) during this phase.
Data collection
Data were extracted using a pre-designed, piloted extrac-
tion form. Working in duplicates and independently re-
viewers extracted the following variables from each
study: study characteristics, baseline patient characteris-
tics, intervention details, and outcomes of interest. Dis-
agreements were resolved by consensus.
Primary efficacy outcomes included: 1) Complete clin-
ical cure, defined as full regression of the lesions; 2)
Clinical improvement of the lesions, defined by a clinical
criteria; 3) Relapse rate, defined as the presence of the
disease after completing the treatment (clinical or bac-
teriological or therapeutic criteria) [10]; 4) Treatment
failure, defined as persistence or worsening of skin le-
sions and failure to improve the bacillary index for MB
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leprosy. Bacillary index (BI) improvement and neuritis
were considered secondary efficacy outcomes. Neuritis
was considered if participants reported pain during the
interview or when participants complains of pain in one
or more peripheral nerve trunks of the limb(s) during
the period of the treatment.
Regarding safety outcome, we evaluated severe side ef-
fects (defined as a side effect that forced the patient to
stop the treatment), and mild to moderate side effects.
Also, we evaluated immunological reactions: type I (re-
verse reaction), and type II (erythema nodosum lepro-
sorum - ENL).
Author contact
We contacted corresponding authors of each study twice
within 2 weeks via e-mail or by phone or mail when e-
mail was not available if additional information was
required.
Quality assessment
We used the Cochrane Collaboration’s tool for assessing
risk of bias [11] to evaluate the methodological quality
of the included RCTs. This was assessed independently
by duplicate for each study. For observational studies,
we used the Newcastle-Ottawa Scale [12].
Statistical analysis and data synthesis
We summarized the qualitative data (eg. study popula-
tion, design, intervention, comparison, outcomes) of the
included studies in tables. If meta-analysis was appropri-
ate, data was pooled using a random effects model to esti-
mate the treatment effects reported as relative risk (RR)
with 95% confidence intervals (CI) [13] for dichotomous
outcomes and mean difference (MD) or standardized
mean difference (SDM) with 95% CI for continuous
outcomes. Statistical heterogeneity was assessed using I2
statistic [14]; I2 values over 50% indicated significant het-
erogeneity across studies’ populations and interventions.
In case data were insufficient for meta-analysis, a descriptive
summary of the outcome findings was reported per
categorization of type of leprosy (PB and MB). If the
primary studies did not report standard deviations so they
had to be inputted using the other studies as reference [15].
Assessment of publication bias
The assessment of publication bias was unfeasible due to
the small number of trials [15].
Results
Search results and study description
The primary search strategy identified 480 references.
After initial screening, 135 studies were eligible to full
text screening. Finally, 25 studies (22 RCTs, a case-
Fig. 1 Flowchart of the study
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control study and 2 non-randomized trial) met our in-
clusion criteria and were included in our review (Fig. 1).
One study does not have the full text available and we
contacted the corresponding author without getting an
answer. Also, another author was contacted to ask the
author about the study design without a successful an-
swer. No unpublished studies were identified.
The included studies (Tables 1 and 2) enrolled 8214
patients with a mean age of 35.2 years (range: 6 to 75
years). Eleven studies evaluated patients with PB leprosy
(4281 patients), while 9 evaluated patients with MB lep-
rosy (3869) patients) and 1 included patients from both
groups. Follow up period ranged from 3months to 12
years. All the studies were conducted in the developing
Fig. 2 Risk of bias of the selected studies
Fig. 3 Complete cure in patients with PB leprosy: MDT vs. ROM. a. At 6 months b. At the end of follow-up period
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Table 3 Efficacy Outcomes
Complete Clinical Cure
Study Patients Comparison Follow up RR 95% CI p value
Balagon, 2010 [18] PB MDT vs. 28 days of RFP + ofloxocin for 4w then 5 months of placebo 6m 4.2 2.25–7.85 < 0.05
12 m 0.93 0.80–1.09 0.38
Bathe, 1986 [19] MDT vs. MDT+ clofazimine in alternative days for 6 m 6m 1.25 0.77–2.04 0.37
24 m 1.09 0.93–1.27 0.29
Orege, 1990 [26] MDT vs. Modified MDT (MDT + RFP + dapsone)a 6 m 0.76 0.61–0.95 0.02
Clinical Improvement
Study Patients Comparison Follow up MDT Control
Rao, 2009 [27] PB MDT vs RFP + dapsone + clofazimine (good) 24 m 6/11 (52%) 7/9 (78%)
MDT vs RFP + dapsone + clofazimine (moderate) 3/11 (27%) 2/9 (22%)
MB MDT vs RFP + dapsone + clofazimine (good) 13/17 (77%) 1/4 (25%)
MDT vs RFP + dapsone + clofazimine (moderate) 3/17 (17%) None
Sampoonachut, 1997 [36] MDT vs. MDT + ofloxacin. 36 m 66.70% 73.30%
MDT vs. ofloxacin + clofazimine, then MDT 66.70% 76.50%
Tejasvi, 2006 [39] MDT vs. RFP + Sparfloxacin + clarithromycin + minocycline 12 m 66.66% 73.92%
Villahermosa, 2004 [40]b MDT vs. ROM 96m 22 points 20 points
Relapse
Study Patients Comparison Follow up RR 95% CI p value
Balagon, 2010 [18] PB MDT vs. 28 days of RFP + ofloxacin for 4w then 5 m of placebo 12 m 1.76 0.16–18.88 0.64
Katoch, 1999 [22] MDT vs. MDT+ clofazimine 24 m 5 0.24–103.28 0.3
Kumar, 2015 [23] MDT vs. ROM 24m 0.5 0.05–5.45 0.57
96 m 1.7 0.94–3.07 0.08
Manickam, 2012 [24] MDT vs. ROM 6m 1.43 0.56–3.64 0.46
Fajardo 2009 [30] MB MDT 2y vs. MDT 1y + 1 month daily RFP/ofloxacin 144 m 0.51 0.05–5.46 0.58
MDT 2y vs. 1 month daily RFP/ofloxacin 0.11 0.02–0.87 0.04
MDT 2y vs. MDT 1 y 0.05 0.01–0.37 < 0.05
Olivera Penna, 2017 [35] MDT vs. RFP+ dapsone + clofazimine × 6 m 60m 0.16 0.02–1.29 0.08
Souza Cunha, 2012 [38] MDT 1y vs. MDT x 2y 84 m 2.59 0.13–52.17 0.53
MDT 1y vs. MDT + ofloxacin 1.04 0.15–7.10 0.97
MDT 1y vs. ofloxacin + RFP 0.13 0.03–0.51 < 0.05
Villahermosa, 2004 [40] MDT vs. ROM 96m No events reported
BI
Study Patients Comparison Follow up MD 95% CI p value
Bathki, 1992 [29] MB MDT vs. MDT + vaccine 24 m 1.3 0.48, 2.12 < 0.05
Gunawan 2018 [32] MDT vs. CDC 3m 0.03 −0.03,0.09 0.75
Jadav, 1992 [33] MDT vs. RFP + dapsone + clofazimine 24 m 0.41 0.12, 0.70 < 0.05
Olivera Penna, 2017 [35] MDT vs. RFP+ dapsone + clofazimine × 6 m 60m − 0.15 −1.06,0.76 0.34
Sampoonachut, 1997c [36] MDT vs. MDT + ofloxacin. 36 m −0.07 − 0.48, 0.34 0.74
MDT vs. Ofloxacin + clofazimine, then MDT −0.68 −1.10, − 0.26 < 0.05
Shaw, 2003c [37] MDT vs. RFP + clofazimine+ acedapsone + dapsone 24 m 0.1 − 0.34, 0.54 0.66
Abbreviations. - BI Bacillary index, CDC Clarithromycin+ dapsone+ clofazimine, m Months, MDT Multidrug treatment, ROM Rifampin, ofloxacin
and minocycline
aIncluded a period of direct observation
bMaximum Improvement score at the end of treatment; no other information reported
cSD not reported
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world, being India the most common country (11
studies).
Comparison treatments varied between studies. The
most common treatment was a single monthly dose of
rifampin, ofloxacin and minocycline (ROM) used in 8
studies (6 of PB and 2 of MB leprosy). The outcomes
evaluated were also markedly heterogeneous, as it can be
seen in Tables 1 and 2.
Quality assessment
The overall risk of bias of the included trials was consid-
ered moderate to high. The vast majority of the studies
did not clearly report the items evaluated. Most of the
included trials reported they attrition rate during the fol-
low up (18 out of 20), with a mean of 10.5% (Fig. 2).
One observational study was included. Quality was eval-
uated using the Newcastle- Ottawa scale. Details are pre-
sented in Additional file 2.
Outcomes of interest
Efficacy outcomes
Complete clinical cure Complete clinical cure was eval-
uated in 9 studies that included patients with PB leprosy.
It was not evaluated in MB leprosy.
A meta-analysis of 5 studies comparing MDT vs.
ROM did not show statistically significant difference be-
tween them after 6 months of treatment (RR 1.06, 95%
CI 0.88–1.27, p = 0.56). When the same comparison was
evaluated at the end of the study period (range 6–36
months) in 6 studies, ROM was not better than MDT
(RR 1.01, 95% CI 0.78–1.31, p = 0.93). The studies with
more participants that were included in the analysis had
significant and contrary results with RR of 1.14 (95%CI
1.02–1.27) by Babu et al., 1997 and 0.73 (95% CI 0.69–
0.77) by Manickam et al., 2012 (Fig. 3a and b).
The addition of clofazimine to PB MDT did not show
significant improvement. This and other available com-
parisons are shown in Table 3.
Clinical improvement This outcome was assessed in 5
studies evaluating PB leprosy and in 3 evaluating MB
leprosy. All of them used clinical scores that considered
the characteristics of the lesions. Evaluated criteria
included erythema, hypopigmentation, infiltration,
anesthesia, nerve involvement and size. Since the
scoring systems were not consistent between studies,
we decided to analyze this outcome using standard-
ized mean difference (SMD).
A meta-analysis of 4 studies comparing MDT vs.
ROM in patients with PB leprosy showed a difference
between both treatments (Standard mean difference −
1.33 (95% CI -1.43- -1.23)). However, this difference was
led by one study with significant results and high num-
ber of participants (Manickam 2012), additionally the I2
show great heterogeneity (Fig. 4). Also, the addition of
clofazimine to MDT did not show any significant im-
provement in this population (SMD 0.28, 95% CI -0.16-
0.72, p = 0.22).
Two of the studies (Sampoonachut 1997 and Tejasvi
2006) evaluating patients with MB leprosy reported clin-
ical improvement as a dichotomous outcome; none of
them reported enough information for the development
of a pooled estimated. Villahermosa 2004 reported an
improvement score (Table 3).
Treatment failure Three studies evaluating PB leprosy
patients included treatment failure as their outcomes.
These studies evaluated MDT vs. ROM in PB leprosy
and no statistically significant difference between the
treatment arms was found (Fig. 5).
Relapse This outcome was evaluated in 8 studies. Two
studies used ROM as their comparison for patients with
PB leprosy and one for MB leprosy. The pooled estimate
of the studies in patients with PB leprosy showed no dif-
ference between both regimes (RR 1.62, 95% CI 0.98–
2.67, p = 0.06) but there seem to be a tendency to favor
ROM (Fig. 6). The big difference in follow up periods
complicates the interpretation of this estimate (6 months
Fig. 4 Clinical improvement in patients with PB leprosy: MDT vs. ROM at the end of follow up period
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vs. 8 years). Additionally, the study evaluating MB lep-
rosy did not report any relapses.
None of the regimes evaluated showed any benefit
over MDT for patients with PB leprosy or MB leprosy
(Table 3).
Bacillary index (BI) improvement BI was exclusively
reported for MB leprosy. Six studies evaluated this out-
come. In this case, most of the alternate regimes
achieved better reductions of BI compared to MDT. De-
tailed results are reported in Table 3.
Safety outcomes
Side effects We intended to evaluate mild-moderate
and severe side effects independently; unfortunately,
most studies did not report their outcomes in this way.
The development of side effects was analyzed as a single
outcome.
Three studies reported side effects in patients with PB
leprosy. No statistically significant difference was seen in
patients receiving MDT or ROM (Fig. 7).
This outcome was reported in 4 studies evaluating
patient with MB leprosy. Each study evaluated a dif-
ferent comparison. Individual estimates are reported
in Table 4.
Immunological reactions
Type I reaction This outcome was evaluated in 11 stud-
ies (6 PB and 5MB). A meta-analysis comparing MDT
vs. ROM in patients with PB leprosy did not show a sta-
tistically significant difference between the interventions
(RR 0.99, 95%CI 0.31–3.18, p = 0.99, Fig. 8). Other stud-
ies evaluating this outcome are reported in Table 4.
Type II reaction This outcome was evaluated in 9 stud-
ies (1 PB and 8MB). We were not able to develop a
meta-analysis. In patients with MB leprosy the combin-
ation of dapsone, rifampin and clofazimine showed a sta-
tistically significant reduction in the development of type
II reaction. On the other hand, the use of MDT regimen
for 2 years increased the development of this outcome in
the same population when compared to the use of MDT
for 1 year. No other statistically significant differences
were observed (Table 4).
Neuritis The development of neuritis was evaluated in 7
studies (3 PB and 4MB). When MDT was compared to
rifampin, dapsone and clofazimine for 6 months in pa-
tients with MB leprosy a statistically significant differ-
ence between groups was seen (Table 4).
Discussion
Main findings
This study aimed to summarize all the evidence available
on WHO MDT treatment effectiveness, safety and im-
munological reactions for leprosy. One of the aspects
that surprised us the most was to see the poor scientific
production for a thousand-year-old disease, the lack of
standardization in definition of diagnostic criteria, out-
come objectives and time for follow up and if we add to
Fig. 5 Treatment failure in patients with PB leprosy: MDT vs. ROM at the end of follow up period
Fig. 6 Relapse rate in patients with PB leprosy: MDT vs. ROM at the end of follow up period
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this the poor methodological quality of the majority of
studies found, show us a situation that support the
denomination and let us understand what leprosy is a
neglected disease.
It was precisely this potentially high risk of bias studies
that did not let bring a consensus: MDT seems to have a
better treatment outcome (clinical improvement) com-
pared with ROM at the end of the follow up period,
however we did not find differences in complete cure at
6 months of treatment or at the end of follow up period.
When MDT is compared with other treatment, we did
not find differences in treatment outcomes.
MDT, as is noted above, had almost no difference in a
better response for cured and reduced relapse rate, com-
pared with ROM and other treatments schemes, since
most of the magnitudes of these differences are small.
However, these schemes had a great success rate after 1
or 2 years of follow-up. These results can confirm the
useful role of MDT in leprosy treatment, however also
reveals gaps in the evidence to improve it: there is lack
of information about adherence in these long-time treat-
ments (MDT, ROM and others), together with the lack
of resistance pattern of relapse cases, this successful
treatment scheme can be in jeopardized by the increas-
ing rate of relapse cases and the unknown effect of re-
sistance epidemiology of M. leprae [8, 41, 42]. Recently
the new guidelines of WHO states that “The same 3-
drug regimen of rifampicin, dapsone and clofazimine
may be used for all leprosy patients, with a duration of
treatment of 6 months for PB leprosy and of 12 months
for MB leprosy. (Strength: conditional, quality of evi-
dence: low)”. However, they mentioned that “evidence
on the potential benefits and harms of a shorter (6-
month) 3-drug regimen was limited and inconclusive,
with a potential increase in the risk of relapse. Therefore,
the Guideline Development Group determined that
there was not enough evidence of equivalent outcomes
to support a recommendation to shorten the treatment
duration for MB leprosy” [43]”. The decision was taken
based in only one study [27] which, although it shows an
interesting design, its non-randomized and has a very
low quality of evidence [44]. Also, the study has not
been valued in comparison with other studies, and
besides these, its findings had not been supported by a
RCT [35].
Is in this context, where supported treatment are
required (leprosy programs were reduced their support
in the last years) [8], new treatment schemes are needed,
considering WHO MDT had more than 30 years of use.
However, new treatment should be based in evidence
and not only in logistical aspects.
Limitations and strengths
This study has limitations: primary studies showed high risk
of bias, specifically regarding allocation and blinding. Also,
most of the studies did not report treatment adherence (a
factor for poor treatment outcomes) or comorbidities such
as HIV/AIDS that can affect treatment outcomes. Other
confounders such as age, gender, and previous treatment
should be also considered in the analysis. These limitations
can affect (in any direction and in magnitude) the measures
of associations reported in primary studies. Another limita-
tion of primary studies was the heterogeneous report of
treatment outcomes, so a proper comparison between
treatments was very difficult, e.g. almost a third part of
treatment outcome evaluation was with different clinical
scores, which applied diverse items and can be affected by
evaluator bias. Future studies evaluating clinical effective-
ness of leprosy treatment should be use standard treatment
outcomes, with laboratory definitions and/or biomarkers of
success, with the aim to compare different settings and clin-
ical characteristics.
Finally, none of these studies reported antibiotic resist-
ance pattern of M. leprae. There are reports on drug re-
sistance in leprosy patients [45–49] and can be one of
the reasons of the relapse rate increase in the last years
[50]. Considering some of the areas with leprosy had
also high incidence of resistant tuberculosis (such us
India) and MDT share rifampin as an important drug
with sensitive tuberculosis, closer follow-up and drug re-
sistance studies should be done in these areas.
However, it is important to mention that studies with
people with leprosy are conducted in low resources set-
tings where sophisticated methods of follow-up are not
possible, due to lack of money and interest of higher
authorities.
Fig. 7 Adverse events in patients with PB leprosy: MDT vs. ROM at the end of the follow up period
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Implications for practice and research
As a stigmatizing disease for centuries, leprosy is now-
adays affecting vulnerable populations in the tropics (es-
pecially in rural and semi-rural areas), where health
systems are weak and other diseases (such as dengue,
malaria, HIV/AIDS or tuberculosis) have more
preponderance in public health funding [51, 52]. Health
determinants affects in several areas (such as poverty,
education, water and sanitation, gender and others), rea-
son why treatment alone is not the most effective way to
eliminate the disease [53]. In addition, leprosy control
faces many barriers regarding clinical management,
Table 4 Safety Outcomes and Immunological Reactions
Side Effects
Study Patients Comparison Follow up RR 95% CI p value
Balagon, 2010 [18] PB MDT vs. 28 days of RFP + ofloxacin for 4w then 5m of placebo 12 m 0.38 0.10–1.39 0.14
Gunawan 2018 [32] MB MDT vs. CDC 3 m Unable to analyze
Tejasvi, 2006 [39] MDT vs. RFP + sparfloxacin + clarithromycin + minocycline 12 m 0.1 0.01–1.56 0.1
Shaw, 2003 [37] MDT vs. RFP + clofazimine+ acedapsone + dapsone 24 m 1.42 0.58–3.47 0.44
Type I reaction
Study Patients Comparison Follow up RR 95%CI p value
Orege, 1990 [26] PB MDT vs. MDT + RFP + dapsonea 6 m 1.15 0.58–2.27 0.69
Fernandes Pena 2012 [31] MB MDT vs. Monthly RFP, dapsone and clofazimine daily × 6 m 60m 1.1 0.86–1.41 0.44
Sampoonachut, 1997 [36] MDT vs. MDT + ofloxacin 12 m 2.11 0.21–21.36 0.53
MDT vs. Ofloxacin + clofazimine, then MDT 1 0.16–6.38 1
Shaw, 2003 [37] MDT vs. RFP + Clofazimine+ Acedapsone + dapsone 24 m 1.78 0.53–5.97 0.35
Tejasvi, 2006 [39] MDT vs. RFP + sparfloxacin + clarithromycin + minocycline 12 m 0.21 0.01–3.71 0.29
Villahermosa, 2004 [40] MDT vs. ROM 96m 0.91 0.37–2.23 0.83
Type II reaction
Study Patients Comparison Follow up RR 95% CI p value
Babu, 1997 [17] PB MDT vs. ROM 18m No events reported
Balagon, 2011 [28] MB MDT 1y vs. MDT 2y 24 m 1.53 1.05–2.23 0.03
Fernandes Pena 2012 [31] MDT vs. Monthly RFP, dapsone and clofazimine daily × 6 m 60m 1.15 0.72–1.84 0.56
Jadhav, 1992 [33] MDT vs. RFP + dapsone + clofazimine 24 m 0.22 0.07–0.72 0.01
Maghanoy, 2018 [34] MDT vs. MDT + 12 months of clofazimine 24 m 0.86 0.52–1.40 0.54
Sampoonachut, 1997 [36] MDT vs. MDT + ofloxacin. 24 m 0.7 0.13–3.75 0.68
MDT vs. ofloxacin + clofazimine, then MDT 1 0.16–6.38 1
Shaw, 2003 [37] MDT vs. RFP + clofazimine+ acedapsone + dapsone 24 m 0.44 0.04–4.45 0.49
Tejasvi, 2006 [39] MDT vs. RFP + sparfloxacin + clarithromycin + minocycline 12 m No events reported
Villahermosa, 2004 [40] MDT vs. ROM 96m 0.91 0.16–5.30 0.92
Neuritis
Study Patients Comparison Follow up RR 95% CI p value
Manickam, 2012 [24] PB MDT vs. ROM 6m 0.5 [0.05, 5.49] 0.57
Bathe, 1986 [19] MDT vs. MDT+ clofazimine 24 m 4 [0.47, 34.24] 0.21
Katoch, 1999 [22] MDT vs. MDT+ clofazimine 24 m No events reported
Fernandes Pena 2012 [31] MB MDT vs. RFP, dapsone and clofazimine × 6m 60m 0.64 0.45, 0.92 0.01
Jadhav, 1992 [33] MDT vs. RFP + dapsone + clofazimine 24 m 0.29 0.03–2.69 0.28
Sampoonachut, 1997 [36] MDT vs. MDT + ofloxacin 24 m 2.11 0.21, 21.36 0.53
MDT vs. ofloxacin + clofazimine, then MDT 1 0.16–6.38 1
Shaw, 2003 [37] MDT vs. RFP + clofazimine+ acedapsone + dapsone 24 m 1.19 0.31–4.51 0.8
Abbreviations - BI Bacillary index, CDC Clarithromycin+dapsone+clofazimine, RFP Rifampin; m: months, MDT Multidrug treatment, ROM, rifampin, ofloxacin
and minocycline
aIncluded a period of direct observation,
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starting with the lack of funding for research, its charac-
teristic as a silent disease, and unavailable measures for
prevention (i.e. an effective vaccine). A delayed diagnosis
and treatment usually lead to disability, which regardless
the success of treatment, will lead to the necessity of ac-
cess to health care and rehabilitation for long time,
sometimes lifelong [54]. In addition, there are not new
drugs in the pipeline to reduce treatment duration, and
the only drug in research phase is bedaquiline (which is
also one of the new drugs for tuberculosis after more
than 30 years of tuberculosis treatment), which showed a
bactericidal effect against M. leprae in animal models
[55, 56]. Now, Bedaquiline is being tested in a Phase 2
trial (not started yet) for MB leprosy in Brazil [57], how-
ever, as in the case of tuberculosis, we need new drugs
that can be combined to reduce the burden of M. leprae,
specially in an context of increasing antibiotic resistance,
providing a safe and short leprosy treatment.
Conclusions
None of the evaluated regimes showed any benefit over
MDT for patients with PB or MB for relapses. The
addition of clofazimine to PB MDT did not show signifi-
cant improvement.
It is necessary to standardize criteria for diagnosis,
cure, and follow-up in the search for more and better
evidence to fill existing gaps in information that evalu-
ates the new available antibiotics.
Further studies evaluating adherence to the treatment,
potential development of drug resistance and short treat-
ment regimens based in evidence are needed to reach
the goal of leprosy elimination.
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